Full Text
The Budget Impact Analysis of Nilotinib in the Second-Line Treatment of Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia

Abstract

Authors

C Huang L Shen Y LIU

Back to Volume 21, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×